Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

19 May 2010 15:32

RNS Number : 2180M
Cathay International Holdings Ld
19 May 2010
 



 

19 May 2010

 

Cathay International Holdings Limited

Interim Management Statement

 

Cathay International Holdings Limited (the "Company") announces its Interim Management Statement for the period from 1 January 2010 to 14 May 2010:

 

Highlights of the period

 

·; On 21 January 2010, the Company announced, inter alia, the appointment of Mr. Lee Jin Yi as an executive director and Chief Executive Officer of the Company and the appointment of Mr Eric Siu as Finance Director of the Company.

 

·; On 12 February 2010, the Company announced further investments in Xian Haotian Bio-Engineering Technology Co. Limited ("Xian Haotian") and its subsidiaries and related companies (the "Xian Haotian Group").

 

·; On 1 April 2010, the Company announced the flotation of Lansen Pharmaceutical Holdings Company Limited ("Lansen"), a subsidiary of the Company, on the Hong Kong Stock Exchange, and the associated partial disposal of Lansen.

 

·; On 27 April 2010, the Company announced the preliminary annual results of the Group for the year ended 31 December 2009.

 

·; On 6 May 2010, the Company announced the successful closing of the placing and public offer of shares in Lansen.

 

Further investments in the Xian Haotian Group

 

On 12 February 2010, the Company announced further investments in the Xian Haotian Group, following which Xian Haotian is now an indirectly wholly owned subsidiary of the Company. The investment made in the Xian Haotian Group during the period was approximately US$13 million, which brings the total investment made to date to approximately US$33 million.

The Xian Haotian Group is one of the Company's major investments in the healthcare and pharmaceutical sector in China. Going forward, inositol will be the core product of the Xian Haotian Group, and the Company anticipates that the inositol business will become a major contributor to the growth in the Group's profits in 2011 and beyond. The inositol project is expected to commence production in the second half of 2010.

 

Flotation and Partial Disposal of Lansen

 

As announced on 6 May 2010, the public offer of shares in Lansen was approximately 852 times oversubscribed and the flotation offer price was set at HK$3.91 per share. The net proceeds of the flotation payable to Lansen, after deducting fees and expenses, were approximately HK$350.4 million (US$45.1 million). The net proceeds of the partial disposal received by the Company were approximately HK$114.9 million (US$14.8 million). Dealings in Lansen's shares on the Hong Kong Stock Exchange commenced on 7 May 2010.

 

Following completion of the flotation and the partial disposal, the Company indirectly holds approximately 52.46% of Lansen. Assuming that the over-allocation option provided under the terms of the flotation is exercised in full, the Company will indirectly hold approximately 50.56% of Lansen.

 

The effect of the flotation and partial disposal on the financial position of the Group has been an increase in net assets.

 

The financial performance of the Group in the period since the 2009 year end have been in line with the Company's expectations, and the outlook for the full year remains unchanged that expressed in our preliminary announcement of results on 27 April 2010.

 

Except for the further investment in the Xian Haotian Group and the net proceeds received from the flotation and partial disposal of Lansen, there has been no significant change to the financial position of the Group since that reported as at 31 December 2009.

 

 

For further information, please contact:

 

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

(via Brunswick)

020 7404 5959

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSZKLFFBEFLBBK
Date   Source Headline
2nd Apr 20157:00 amRNSGrant of Share Options
30th Mar 20157:35 amRNSRepeat of Annual Results Announcement RNS 7096I
27th Mar 201512:14 pmRNSAnnual Results for the Year Ended 31 December 2014
25th Mar 20157:00 amRNSHolding(s) in Company
12th Mar 20157:00 amRNSNotice of Annual Results 2014
5th Jan 20159:16 amRNSLansen's New Distribution Agreement
18th Dec 20148:36 amRNSLansen and Haotian Renew Supply Agreement
29th Aug 20149:26 amRNSInterim results for six months ended 30 June 2014
19th Aug 20147:00 amRNSNotice of Interim Results 2014
23rd May 201410:38 amRNSResult of AGM
19th May 20147:00 amRNSInterim Management Statement
7th Apr 20148:58 amRNSGrant of Share Options
31st Mar 20147:00 amRNSAcquisition of Sicorten Plus in the PRC
28th Mar 20148:47 amRNSAnnual Results for the Year Ended 31 December 2013
14th Mar 20147:00 amRNSNotice of Annual Results
19th Nov 20137:00 amRNSInterim Management Statement
15th Oct 201310:24 amRNSTransfer of Misoprostol Development Project
3rd Sep 20131:31 pmRNSLansen and Haotian Sign Supply Agreement
30th Aug 20139:42 amRNSInterim Results for the six months ended June 2013
19th Aug 20139:24 amRNSNotice of Interim Results
21st May 20137:00 amRNSResults of Annual General Meeting
16th May 20137:00 amRNSInterim Management Statement
11th Apr 20137:00 amRNSAnnual Report and Accounts
4th Apr 20139:03 amRNSGrant of Share Options
27th Mar 20138:30 amRNSAnnual Results for the Year Ended 31 December 2012
14th Mar 20139:33 amRNSNotice of Annual Results 2012
6th Mar 20138:30 amRNSCathay's subsidiary Lansen board change
26th Feb 201310:37 amRNSTR-1: Notification of Major Interest in Shares
23rd Nov 20128:55 amRNS1.5% holding in Zhejiang Starry Pharmaceutical Co.
19th Nov 20127:00 amRNSInterim Management Statement
29th Aug 201212:15 pmRNSTotal Voting Rights and Share Capital
29th Aug 20129:23 amRNSInterim results
15th Aug 20127:00 amRNSNotice of Interim Results
25th May 201211:26 amRNSResult of AGM
21st May 20127:00 amRNSAnnual Information Update
17th May 20127:00 amRNSInterim Management Statement
10th May 20127:00 amRNSLicense for collagen injectable filler
20th Apr 20129:15 amRNSAnnual Report and Accounts
3rd Apr 201210:50 amRNSGrant of Share Options
29th Mar 20129:32 amRNSAnnual Results for the Year Ended 31 December 2011
19th Mar 201210:00 amRNSNotification of Annual Results
27th Feb 20129:43 amRNSLansen Received Technology Endorsement
9th Jan 20129:00 amRNSLansen signs exclusive agreement
18th Nov 20117:00 amRNSInterim Management Statement
26th Oct 20119:47 amRNSLansen signs exclusive agreement with Ethypharm
25th Aug 20115:00 pmRNSInterim Results
15th Aug 201111:12 amRNSNotice of Interim Results
20th May 20117:00 amRNSAnnual Information Update
19th May 20117:00 amRNSInterim Management Statement
6th Apr 20117:00 amRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.